Clinic
Dyersburg Family Walk-In Clinic
Dyersburg Family Walk-In Clinic was paid $15.74M by Medicaid between Jan 2018 and Dec 2024, across 115 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 41% of everything it billed.
33Billing provider infoDYERSBURG FAMILY WALK-IN CLINIC
DYERSBURG, TN 38024
DYERSBURG, TN 38024
33aNPI1174712780assigned 10/19/2007
33bProvider typePrimary Care Clinic/Center
28Total paid$15.74M
24GClaims1,031,095
24DCodes billed115
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Primary Care Clinic/Center providers in Tennessee
Rank by total paid#4 of 139
Median peer was paid$101K
This provider vs. median156×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 97,981 | $1.62M | |
| 2019 | 122,194 | $1.91M | |
| 2020 | 106,683 | $1.88M | |
| 2021 | 164,550 | $2.67M | |
| 2022 | 190,393 | $2.70M | |
| 2023 | 182,478 | $2.71M | |
| 2024incomplete | 166,816 | $2.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 41% | 172,576 | 148,051 | $6.44M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 61,372 | 52,332 | $3.22M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.1% | 21,549 | 18,299 | $641K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 3.6% | 24,715 | 21,558 | $574K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.0% | 44,910 | 20,065 | $468K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.9% | 50,726 | 45,615 | $460K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.9% | 34,592 | 24,689 | $450K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.5% | 18,163 | 8,268 | $392K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 2.2% | 10,923 | 9,621 | $353K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.2% | 8,409 | 7,382 | $351K |
| 87428 | 1.8% | 5,055 | 4,482 | $278K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 10,454 | 9,319 | $263K |
103 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.6% | 4,304 | $250K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 1.6% | 3,625 | $244K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | 1.5% | 4,892 | $230K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,190 | $129K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 6,726 | $115K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 1,551 | $104K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,651 | $103K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,621 | $86K |
| 92552 | <1% | 3,324 | $50K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 9,289 | $45K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,252 | $44K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 585 | $43K |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,169 | $36K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 313 | $31K |
| 87807 | <1% | 2,968 | $28K | |
| 99460 | <1% | 685 | $28K | |
| 3008F | <1% | 160,458 | $27K | |
| 99177 | <1% | 3,975 | $25K | |
| 99462 | <1% | 649 | $19K | |
| 81002 | <1% | 8,080 | $15K | |
| 3074F | <1% | 83,249 | $14K | |
| 3078F | <1% | 74,386 | $14K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,786 | $13K |
| 54150 | <1% | 88 | $13K | |
| 96127 | <1% | 3,148 | $13K | |
| 81003 | <1% | 8,957 | $13K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 727 | $12K |
| 99173 | <1% | 2,748 | $12K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,544 | $10K |
| 96160 | <1% | 1,173 | $9K | |
| 81025 | <1% | 1,656 | $6K | |
| 3079F | <1% | 27,115 | $6K | |
| 94760 | <1% | 10,544 | $6K | |
| 93000 | <1% | 431 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,269 | $5K |
| 83655 | <1% | 405 | $4K | |
| 90461 | <1% | 16,908 | $3K | |
| 90686 | <1% | 665 | $3K | |
| 3077F | <1% | 10,482 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 36 | $3K |
| 80305 | <1% | 358 | $3K | |
| 90697 | <1% | 1,467 | $2K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,702 | $2K |
| 92551 | <1% | 358 | $2K | |
| 96161 | <1% | 538 | $2K | |
| 3080F | <1% | 4,333 | $2K | |
| 3075F | <1% | 12,251 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,103 | $2K |
| 90756 | <1% | 97 | $2K | |
| 99384 | <1% | 16 | $1K | |
| 99383 | <1% | 17 | $1K | |
| 83037 | <1% | 249 | $1K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 85 | $1K |
| 99382 | <1% | 12 | $893.19 | |
| 90677 | <1% | 921 | $875.36 | |
| 90670 | <1% | 2,558 | $720.89 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 215 | $701.86 |
| 1159F | <1% | 679 | $701.29 | |
| 1160F | <1% | 577 | $676.99 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 615 | $510.98 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 130 | $480.72 |
| 87220 | <1% | 202 | $451.59 | |
| 94060 | <1% | 15 | $405.51 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 43 | $389.20 |
| 90710 | <1% | 266 | $375.00 | |
| 87210 | <1% | 174 | $367.92 | |
| 82120 | <1% | 264 | $325.43 | |
| 90633 | <1% | 1,203 | $319.46 | |
| 90698 | <1% | 947 | $310.93 | |
| 90651 | <1% | 259 | $294.18 | |
| 90707 | <1% | 76 | $293.07 | |
| 90671 | <1% | 255 | $265.63 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 40 | $265.49 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 368 | $236.51 |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | <1% | 16 | $186.38 |
| 90716 | <1% | 64 | $172.17 | |
| 90734 | <1% | 92 | $165.61 | |
| 85018 | <1% | 105 | $147.40 | |
| 90688 | <1% | 248 | $147.04 | |
| 90696 | <1% | 134 | $141.46 | |
| 90680 | <1% | 2,109 | $88.98 | |
| 90744 | <1% | 501 | $62.01 | |
| 86308 | <1% | 14 | $48.02 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14 | $42.43 |
| 90674 | <1% | 102 | $35.97 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $28.09 |
| 90656 | <1% | 107 | $26.40 | |
| 94150 | <1% | 16 | $17.75 | |
| 1157F | <1% | 240 | $12.18 | |
| 99000 | <1% | 3,215 | $4.57 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 19 | $3.31 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 16 | $0.52 |
| 90685 | 0% | 39 | $0.00 | |
| 90715 | 0% | 100 | $0.00 | |
| 90700 | 0% | 52 | $0.00 | |
| 1158F | 0% | 61 | $0.00 | |
| 90381 | 0% | 91 | $0.00 | |
| 4037F | 0% | 83 | $0.00 | |
| 90647 | 0% | 42 | $0.00 | |
| 90619 | 0% | 43 | $0.00 | |
| 1170F | 0% | 62 | $0.00 | |
| 1000F | 0% | 16 | $0.00 | |
| 1125F | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWRIGHT, SHERYL (CEO / PRESIDENT)